טבע מודיעה על אישור ה- FDA ל- ArmonAir® Digihaler™ אבקת שאיפה (fluticasone propionate)

פורטפוליו המשאפים הדיגיטליים של טבע כולל כעת מוצרים משלוש מתוך הקטגוריות הנפוצות ביותר של טיפולי אסתמה

תל אביב ופרסיפני ניו ג'רזי, 24 בפברואר 2020 - טבע Respiratory, LLC, שלוחה של טבע תעשיות פרמצבטיות בע"מ NYSE  ו-TASE: TEVA) הודיעה היום כי מינהל המזון והתרופות האמריקני (FDA) אישר את ™ArmonAir® Digihaler אבקת שאיפה, קורטיקוסטרואיד בשאיפה (ICS) המועבר באמצעות מכשיר ™Digihaler של טבע, המכיל חיישנים מובנים והמתחברת ליישומון נלווה (אפליקציה) למכשיר נייד המספק מידע על השימוש במשאף עבור אנשים עם אסתמה.  ™ArmonAir® Digihaler מיועד לטיפול תחזוקתי באסתמה בחולים מגיל 12 ומעלה. ™ArmonAir® Digihaler אינו מיועד להקלה בעווית סימפונות חריפה.

™ArmonAir® Digihaler מצטרף לפורטפוליו המוצרים המאושרים של ™Digihaler, הכולל את  ™ProAir® Digihaler 
(albuterol sulfate 117 mcg) אבקת שאיפה, המיועדת לשימוש בחולים מגיל 4 ומעלה לטיפול או מניעה של עווית סימפונות אצל אלו שיש להם מחלת חסימת דרכי נשימה הפיכה ולמניעת עווית סימפונות הנגרמת על ידי פעילות גופנית, ו- ™AirDuo® Digihaler אבקת שאיפה, המיועדת לטיפול בתחזוקת אסתמה בקרב חולים בני 12 ומעלה. מכשיר ה- ™Digihaler מזהה את השימוש במשאף ומודד קצב זרימה שאיפתי. נתונים אלה נשלחים לאחר מכן לאפליקציה סלולרית נלווית באמצעות טכנולוגיית Bluetooth® Wireless, כך שמטופלים יוכלו לעיין בנתונים שלהם לאורך זמן, ובמידת הצורך לשתף אותם עם נותני שירותי הבריאות שלהם כדי לקיים דיונים מושכלים יותר על מצבם וטיפולם. מטופלים יכולים גם לתזמן תזכורות בסמארטפון שלהם כדי לקחת את ™ArmonAir® Digihaler או ™AirDuo® Digihaler כפי שנקבע. נא לעיין במידע הבטיחות החשוב עבור מוצרים אלה בהמשך.

"המטופלים שלי מתקשים לעתים קרובות לזכור ליטול את התרופה שלהם ולעקוב אחר השימוש בתרופות התחזוקה וההצלה שלהם, אשר יכולות לשחק תפקיד משמעותי בניהול אסתמה," אמר ד"ר נאביל פרוקי, FAAAAI, FACAAI, המחלקה לרפואה, בית הספר לרפואה באוניברסיטת אינדיאנה. "לאפשר למטופלים לעקוב אחר נתוני השימוש במשאף, כולל תדירות ושיעורי זרימה שאיפתיים, בכל פעם שהם משתמשים במשאף שלהם, יכול למלא תפקיד משמעותי בסיוע עבורי לנהל שיחות פתוחות ומושכלות איתם על הדרך הטובה ביותר לנהל את מצבם."

"האישור של המוצר השלישי בפורטפוליו של ™Digihaler שלנו הוא אבן דרך מרגשת במיוחד עבורנו," אמר סוון דתלפס, סגן נשיא בכיר, שיווק ופורטפוליו עולמי. "הפורטפוליו שלנו כולל כעת טיפול הצלה, טיפול משולב לתחזוקה, וכעת טיפול מונותרפי בתחזוקה. כל שלושת המשאפים הדיגיטליים האלה עם חיישנים מובנים משתלבים עם אפליקציות סלולריות נלוות, ומאפשרים למטופלים לעקוב אחר השימוש במשאף על פני מכשירים דיגיטליים מרובים כדי להבין טוב יותר את מצבם. חולים עשויים גם לבחור לשתף נתונים אלה עם ספקי הבריאות שלהם."

אישור ™ArmonAir® Digihaler מבוסס על בחינת בקשת התרופות המשלימה החדשה (sNDA) שהגישה טבע ל- FDA.

 ™ArmonAir® Digihaler אושר במינון נמוך, בינוני וגבוה: 55 מק"ג, 113 מק"ג ו -232 מק"ג, הנלקחים בשאיפה אחת, פעמיים ביום.

"עשרים וחמישה מיליון אמריקאים חיים עם אסתמה, וחשוב שהם יעקבו אחר השימוש בתרופות שלהם ותדירותם כדי להבטיח שהם מנהלים את המחלה בצורה הולמת", אמרה טוניה וינדרס, נשיא ומנכ"ל רשת האלרגיות והאסטמה "בזכות פיתוחים טכנולוגיים כמו אלה, היכולת לעקוב אחר נתונים מסוג זה עבור סוגים שונים של תרופות לאסתמה יכולה לעזור לחולים לנהל שיחות פתוחות עם נותני שירותי הבריאות שלהם, במטרה להבטיח שהאסתמה שלהם מנוהלת היטב."

פורטפוליו ה- ™Digihaler השלם צפוי להיות זמין מסחרית למטופלים בהמשך השנה.

ARMONAIR® DIGIHALER™ APPROVED USES

ArmonAir® Digihaler™ (fluticasone propionate) inhalation powder is a prescription inhaled corticosteroid (ICS) medicine for the long-term treatment of asthma in patients 12 years and older.

ArmonAir Digihaler is not used to relieve sudden breathing problems from asthma and won't replace a rescue inhaler.

ArmonAir Digihaler contains a built-in electronic module that records and stores information about inhaler events. ArmonAir Digihaler may be used with, and transmits information to a mobile App. ArmonAir Digihaler does not need to be connected to the app in order for you to take your medicine.

ARMONAIR® DIGIHALER™ IMPORTANT SAFETY INFORMATION

  • Do not use ArmonAir Digihaler to treat sudden breathing problems from asthma. Always have a rescue inhaler with you to treat sudden symptoms.
  • Do not use ArmonAir Digihaler if you have a severe allergy to milk proteins or if you are allergic to any of the ingredients in the product. Ask your healthcare provider if you are not sure.
  • Tell your healthcare provider about all the medicines you take and about all of your health conditions.
  • Do not use ArmonAir Digihaler more often than prescribed.
  • Do not stop using ArmonAir Digihaler, even if you are feeling better, unless your healthcare provider tells you to. If you miss a dose of ArmonAir Digihaler, just skip that dose. Take your next dose at your usual time. Do not take 2 doses at 1 time.
  • ArmonAir Digihaler can cause serious side effects, including:
    • fungal infection in your mouth or throat (thrush). Rinse your mouth with water without swallowing after using ArmonAir Digihaler to help reduce your chance of getting thrush.
    • weakened immune system and increased chance of getting infections (immunosuppression). You should avoid exposure to chickenpox and measles, and, if exposed, tell your healthcare provider right away. Worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections, or herpes infection of the eye (ocular herpes simplex) may occur.
    • reduced adrenal function. This can happen when you stop taking an oral corticosteroid (such as prednisone) and start taking a medicine containing an ICS (such as ArmonAir Digihaler). During this transition period, when your body is under stress such as from fever, trauma (such as a car accident), infection, or surgery, adrenal insufficiency can get worse and may cause death. Symptoms of adrenal insufficiency include:
      • feeling tired
      • lack of energy
      • weakness
      • nausea and vomiting
      • low blood pressure
    • serious allergic reactions. Stop using ArmonAir Digihaler and call your healthcare provider or get emergency medical care if you get any of the following symptoms of a serious allergic reaction:
      • rash
      • hives
      • swelling of your face, mouth, and tongue
      • breathing problems
    • bone thinning or weakness (osteoporosis)
    • slowed growth in children. A child's growth should be checked often.
    • eye problems including glaucoma and cataracts. You should have regular eye exams while using ArmonAir Digihaler.
    • increased wheezing (bronchospasm). Increased wheezing can happen right away after using ArmonAir Digihaler. If this occurs, stop using ArmonAir Digihaler and call your healthcare provider. Always have a rescue inhaler with you to treat sudden wheezing.
  • Common side effects of ArmonAir Digihaler include:
    • infection or inflammation of nose and throat (nasopharyngitis)
    • upper respiratory tract infection
    • thrush in your mouth or throat. Rinse your mouth with water without swallowing after use to help prevent this.
    • headache
    • cough
  • These are not all the possible side effects of ArmonAir Digihaler. Call your healthcare provider for medical advice about side effects.
  • You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information for ArmonAir Digihaler.

AIRDUO® DIGIHALER™ APPROVED USES

  • AirDuo Digihaler is a prescription medicine used to control symptoms of asthma and to prevent symptoms such as wheezing in people 12 years of age and older.
  • AirDuo Digihaler is not used to relieve sudden breathing problems from asthma and won't replace a rescue inhaler.

AirDuo Digihaler contains a built-in electronic module that records and stores information about inhaler events. AirDuo Digihaler may be used with, and transmits information to, a mobile App.

AirDuo Digihaler does not need to be connected to the app in order for you to take your medicine.

AIRDUO® DIGIHALER™ IMPORTANT SAFETY INFORMATION

  • AirDuo Digihaler contains salmeterol. Long-acting beta2-agonist (LABA) medicines such as salmeterol when used alone increase the risk of hospitalizations and death from asthma problems. AirDuo Digihaler contains an inhaled corticosteroid (ICS) and a LABA. When an ICS and a LABA are used together, there is not a significant increased risk in hospitalizations and death from asthma problems.
  • Do not use AirDuo Digihaler to treat sudden breathing problems from asthma. Always have a rescue inhaler with you to treat sudden symptoms.
  • Do not use AirDuo Digihaler if you have a severe allergy to milk proteins or if you are allergic to any of the ingredients in the product. Ask your healthcare provider if you are not sure.
  • Do not use AirDuo Digihaler more often than prescribed.
  • Do not take AirDuo Digihaler with other medicines that contain a LABA for any reason.
  • Tell your healthcare provider about all the medicines you take and about all of your health conditions.
  • AirDuo Digihaler can cause serious side effects, including:
  • Fungal infection in your mouth or throat (thrush). Rinse your mouth with water without swallowing after using AirDuo Digihaler to help reduce your chance of getting thrush.
  • Weakened immune system and increased chance of getting infections (immunosuppression). You should avoid exposure to chickenpox and measles, and, if exposed, tell your healthcare provider right away. Worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections, or herpes infection of the eye (ocular herpes simplex) may occur.
  • Reduced adrenal function. This can happen when you stop taking an oral corticosteroid (such as prednisone) and start taking a medicine containing an inhaled corticosteroid (such as AirDuo Digihaler). During this transition period, when your body is under stress such as from fever, trauma (such as a car accident), infection, or surgery, adrenal insufficiency can get worse and may cause death. Symptoms of adrenal insufficiency include:
    • feeling tired
    • lack of energy
    • weakness
    • nausea and vomiting
    • low blood pressure
  • Sudden breathing problems immediately after inhaling your medicine. If you have sudden breathing problems immediately after inhaling your medicine, stop using AirDuo Digihaler and call your healthcare provider right away.
  • Serious allergic reactions. Stop using AirDuo Digihaler and call your healthcare provider or get emergency medical care if you get any of the following symptoms of a serious allergic reaction:
    • rash
    • hives
    • swelling of your face, mouth, and tongue
    • breathing problems
  • Effects on heart
    • increased blood pressure
    • a fast or irregular heartbeat
    • chest pain
  • Effects on nervous system
    • tremor
    • nervousness
  • Bone thinning or weakness (osteoporosis)
  • Slowed growth in children. A child's growth should be checked often.
  • Eye problems including glaucoma and cataracts. You should have regular eye exams while using AirDuo Digihaler.
  • Changes in laboratory blood values (sugar, potassium, certain types of white blood cells)
  • Common side effects of AirDuo Digihaler include:
    • Infection of nose and throat (nasopharyngitis)
    • thrush in your mouth or throat. Rinse your mouth with water without swallowing after use to help prevent this.
    • back pain
    • headache
    • cough
  • These are not all the possible side effects of AirDuo Digihaler. Call your healthcare provider for medical advice about side effects.
  • You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information for AirDuo Digihaler.

PROAIR® DIGIHALER™ APPROVED USES

ProAir® Digihaler™ (albuterol sulfate) Inhalation Powder is a prescription medicine used in people 4 years of age and older to:

  • treat or prevent bronchospasm in people who have reversible obstructive airway disease
  • prevent exercise-induced bronchospasm

ProAir Digihaler contains a built-in electronic module that detects, records and stores inhaler event information. ProAir Digihaler may be used with, and transmits information to, a mobile app. ProAir Digihaler does not need to be connected to the mobile app in order for you to take your medicine.

proair® digihaler™ IMPORTANT SAFETY INFORMATION

  • Do not use ProAir Digihaler (albuterol sulfate) Inhalation Powder if you are allergic to albuterol sulfate, lactose, milk proteins, or any of the ingredients in ProAir Digihaler. Ask your healthcare provider if you have any questions or are not sure
  • Before using ProAir Digihaler, tell your healthcare provider about all of your medical conditions, including if you:
    • have heart problems
    • have high blood pressure (hypertension)
    • have convulsions (seizures)
    • have thyroid problems
    • have diabetes
    • have low potassium levels in your blood
    • are pregnant or planning to become pregnant
    • are breastfeeding or planning to breastfeed
  • Tell your healthcare provider about all the medicines you take, especially:
    • other inhaled medicines or asthma medicines
    • beta blocker medicines
    • diuretics
    • digoxin
    • monoamine oxidase inhibitors
    • tricyclic antidepressants
  • Do not increase your dose or take extra doses of ProAir Digihaler without first talking to your healthcare provider
  • Get medical help right away if ProAir Digihaler no longer helps your symptoms, your symptoms get worse or you need to use your inhaler more often
  • While you are using ProAir Digihaler, do not use other inhaled rescue medicines and asthma medicines unless your healthcare provider tells you to do so
  • ProAir Digihaler may cause serious side effects, including:
    • worsening trouble breathing, coughing and wheezing (paradoxical bronchospasm). If this happens, stop using ProAir Digihaler and call your healthcare provider or get emergency help right away. This is more likely to happen with your first use of a new asthma inhalation medicine
    • heart problems, including faster heart rate and higher blood pressure
    • possible death in people with asthma who use too much ProAir Digihaler
    • allergic reactions. Call your healthcare provider right away if you have the following symptoms of an allergic reaction:
      • itchy skin
      • swelling beneath your skin or in your throat
      • rash
      • worsening trouble breathing
    • changes in laboratory blood values (sugar, potassium)
  • The most common side effects of ProAir Digihaler include:
    • back pain
    • body aches and pain
    • upset stomach
    • sinus headache
    • urinary tract infection
    • your heart feels like it is pounding or racing (palpitations)
    • chest pain
    • fast heart rate
    • shakiness
    • nervousness
    • headache
    • dizziness
    • sore throat
    • runny nose
  • These are not all of the possible side effects of ProAir Digihaler. For more information, ask your healthcare provider or pharmacist
  • You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088

Please read the full Prescribing Information.

 

אודות טבע

טבע תעשיות פרמצבטיות בע"מ (NYSE & TASE: TEVA) מפתחת ומייצרת תרופות לשיפור חייהם של אנשים מזה למעלה ממאה שנה. אנו מובילים גלובליים בגנריקה ובתרופות ייחודיות, עם פורטפוליו הכולל יותר מ- 2,400 מוצרים בכמעט כל תחום טיפולי. בכל יום, קרוב ל-200 מיליון אנשים ברחבי העולם נוטלים תרופה של טבע, הודות לאחת ממערכות התפעול הגדולות והמורכבות בתעשייה הפרמצבטית. נוסף על מעמדנו המבוסס בגנריקה, יש לנו פעילות מחקר חדשני משמעותית התומכת בפורטפוליו המוצרים הייחודיים והביופרמצבטיים הגדל שלנו. למידע נוסף על החברה, בקרו באתר www.Teva.co.il

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

  • uncertainties relating to the potential benefits and success of our new structure and recent senior management changes as well as the potential success and our ability to effectively execute a restructuring plan;
  • our generics medicines business, including: that we are substantially more dependent on this business, with its significant attendant risks, following our acquisition of Allergan plc’s worldwide generic pharmaceuticals business (“Actavis Generics”); our ability to realize the anticipated benefits of the acquisition (and any delay in realizing those benefits) or difficulties in integrating Actavis Generics; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our generic products, both from competing products and as a result of increased governmental pricing pressures; and our ability to take advantage of high-value biosimilar opportunities;
  • our specialty medicines business, including: competition for our specialty products, especially Copaxone®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; our ability to achieve expected results from investments in our product pipeline; competition from companies with greater resources and capabilities; and the effectiveness of our patents and other measures to protect our intellectual property rights;
  • our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a downgrade of our credit ratings;
  • our business and operations in general, including: our ability to develop and commercialize additional pharmaceutical products; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel;the restructuring of our manufacturing network, including potential related labor unrest; the impact of continuing consolidation of our distributors and customers; variations in patent laws that may adversely affect our ability to manufacture our products; our ability to consummate dispositions on terms acceptable to us; adverse effects of political or economic instability, major hostilities or terrorism on our significant worldwide operations; and our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions;
  • compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; governmental investigations into sales and marketing practices; potential liability for sales of generic products prior to a final resolution of outstanding patent litigation; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
  • other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; the significant increase in our intangible assets, which may result in additional substantial impairment charges; potentially significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;


and other factors discussed in our Annual Report on Form 20-F for the year ended December 31, 2016 (“Annual Report”), including in the section captioned “Risk Factors,” and in our other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. 

שתפו מאמר זה

למעבר לכל הכתבות והמאמרים

הקליקו כאן